Codexis looks to future

Codexis' full year 2011 product revenue rose 49% to $49.0m as a result of increased sales to both generic and innovator pharmaceutical customers. Codexis President and CEO, Alan Shaw, said that in 2012 the Codexis' customers received FDA and EMA approvals for three new on-patent drugs using the company's technology. Shaw said he expects to see improved sales growth in 2012. Additionally he said Codexis is expecting the FDA to approve the manufacturing process for blockbuster pharmaceutical product, which has approaching $4bn in sales. He sees additional growth from increased volumes of generic atorvostatin using the company's technology and more companies using their products in their process development.
Codexis